Abstract：
BACKGROUND: Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.
OBJECTIVE: Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.
METHODS: Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.
RESULTS: The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.
CONCLUSIONS: Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
OBJECTIVE: Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.
METHODS: Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.
RESULTS: The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.
CONCLUSIONS: Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
摘要：
背景：患有环磷酰胺失败的淋巴瘤的狗，阿霉素,长春新碱,和泼尼松化疗（CHOP）在完成方案之前通常被认为具有较差的长期结果，但之前没有研究评估早期复发对接受抢救化疗的患者的无进展间期(PFI)或总生存时间(OST)的影响.
目的：将多中心淋巴瘤犬的抢救治疗结果与一线CHOP化疗后的结果相关联。
方法：数据来自先前对187只接受一线CHOP化疗然后接受洛莫司汀（CCNU）的多中心淋巴瘤犬的6项回顾性或前瞻性研究，L-天冬酰胺酶和泼尼松（LAP），或rabacfosadine（RAB，Tanovea),有或没有泼尼松或L-天冬酰胺酶。
结果：CHOP化疗开始后的PFI与进展后的反应率显着相关，PFI,以及两种救援方案的救援后生存时间(ST)。免疫表型（B-vsT细胞）与反应无显著相关，LAP的PFI或OST，但与RAB的反应和PFI显著相关。
结论：在一线CHOP化疗期间或之后经历短PFI的狗对抢救治疗的反应率较低，较短的PFI和ST。免疫表型对LAP的预后无显著影响，但与RAB的PFI相关。
目的：将多中心淋巴瘤犬的抢救治疗结果与一线CHOP化疗后的结果相关联。
方法：数据来自先前对187只接受一线CHOP化疗然后接受洛莫司汀（CCNU）的多中心淋巴瘤犬的6项回顾性或前瞻性研究，L-天冬酰胺酶和泼尼松（LAP），或rabacfosadine（RAB，Tanovea),有或没有泼尼松或L-天冬酰胺酶。
结果：CHOP化疗开始后的PFI与进展后的反应率显着相关，PFI,以及两种救援方案的救援后生存时间(ST)。免疫表型（B-vsT细胞）与反应无显著相关，LAP的PFI或OST，但与RAB的反应和PFI显著相关。
结论：在一线CHOP化疗期间或之后经历短PFI的狗对抢救治疗的反应率较低，较短的PFI和ST。免疫表型对LAP的预后无显著影响，但与RAB的PFI相关。
